These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 32951108)

  • 1. Association of PD-L1 and IDO1 expression with JAK-STAT pathway activation in soft-tissue leiomyosarcoma.
    Iwasaki T; Kohashi K; Toda Y; Ishihara S; Yamada Y; Oda Y
    J Cancer Res Clin Oncol; 2021 May; 147(5):1451-1463. PubMed ID: 32951108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. JAK2 and PD-L1 Amplification Enhance the Dynamic Expression of PD-L1 in Triple-negative Breast Cancer.
    Chen M; Pockaj B; Andreozzi M; Barrett MT; Krishna S; Eaton S; Niu R; Anderson KS
    Clin Breast Cancer; 2018 Oct; 18(5):e1205-e1215. PubMed ID: 29933930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Indoleamine 2,3-dioxygenase 1 and programmed cell death-ligand 1 co-expression correlates with aggressive features in lung adenocarcinoma.
    Kozuma Y; Takada K; Toyokawa G; Kohashi K; Shimokawa M; Hirai F; Tagawa T; Okamoto T; Oda Y; Maehara Y
    Eur J Cancer; 2018 Sep; 101():20-29. PubMed ID: 30014971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-expression of IDO1 and PD-L1 in lung squamous cell carcinoma: Potential targets of novel combination therapy.
    Takada K; Kohashi K; Shimokawa M; Haro A; Osoegawa A; Tagawa T; Seto T; Oda Y; Maehara Y
    Lung Cancer; 2019 Feb; 128():26-32. PubMed ID: 30642449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myricetin inhibits interferon-γ-induced PD-L1 and IDO1 expression in lung cancer cells.
    Chen YC; He XL; Qi L; Shi W; Yuan LW; Huang MY; Xu YL; Chen X; Gu L; Zhang LL; Lu JJ
    Biochem Pharmacol; 2022 Mar; 197():114940. PubMed ID: 35120895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Programmed death ligand 1/indoleamine 2,3-dioxygenase 1 expression and tumor-infiltrating lymphocyte status in renal cell carcinoma with sarcomatoid changes and rhabdoid features.
    Kiyozawa D; Takamatsu D; Kohashi K; Kinoshita F; Ishihara S; Toda Y; Eto M; Oda Y
    Hum Pathol; 2020 Jul; 101():31-39. PubMed ID: 32360490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute myeloid leukemias with JAK2/STAT mutations are associated with PD-L1 upregulation.
    Chai J; Choudhuri J; Wang Q; Fang Y; Shi Y; Kamel J; Shah N; Sica RA; Kornblum N; Konopleva M; Mantzaris I; Shastri A; Gritsman K; Verma A; Goldfinger M; Goel S; Wang Y; Tian X
    Leuk Lymphoma; 2023 Oct; 64(10):1662-1672. PubMed ID: 37424335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of PD-L1, PD-L2, and IDO1 on tumor cells and density of CD8-positive tumor-infiltrating lymphocytes in early-stage lung adenocarcinoma according to histological subtype.
    Takada K; Toyokawa G; Kinoshita F; Jogo T; Kohashi K; Wakasu S; Ono Y; Tanaka K; Oba T; Osoegawa A; Tagawa T; Azuma K; Okamoto I; Shimokawa M; Oda Y; Mori M
    J Cancer Res Clin Oncol; 2020 Oct; 146(10):2639-2650. PubMed ID: 32405745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-L1 Is Upregulated by Simultaneous Amplification of the PD-L1 and JAK2 Genes in Non-Small Cell Lung Cancer.
    Ikeda S; Okamoto T; Okano S; Umemoto Y; Tagawa T; Morodomi Y; Kohno M; Shimamatsu S; Kitahara H; Suzuki Y; Fujishita T; Maehara Y
    J Thorac Oncol; 2016 Jan; 11(1):62-71. PubMed ID: 26762740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune checkpoints indoleamine 2,3-dioxygenase 1 and programmed death-ligand 1 in oral mucosal dysplasia.
    Sieviläinen M; Passador-Santos F; Almahmoudi R; Christopher S; Siponen M; Toppila-Salmi S; Salo T; Al-Samadi A
    J Oral Pathol Med; 2018 Sep; 47(8):773-780. PubMed ID: 29851145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-L1 and IDO1 expression and tumor-infiltrating lymphocytes in osteosarcoma patients: comparative study of primary and metastatic lesions.
    Toda Y; Kohashi K; Yamada Y; Yoshimoto M; Ishihara S; Ito Y; Iwasaki T; Yamamoto H; Matsumoto Y; Nakashima Y; Mawatari M; Oda Y
    J Cancer Res Clin Oncol; 2020 Oct; 146(10):2607-2620. PubMed ID: 32388585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-L1 and IDO1 Are Expressed in Poorly Differentiated Thyroid Carcinoma.
    Rosenbaum MW; Gigliotti BJ; Pai SI; Parangi S; Wachtel H; Mino-Kenudson M; Gunda V; Faquin WC
    Endocr Pathol; 2018 Mar; 29(1):59-67. PubMed ID: 29372535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-375 inhibits IFN-γ-induced programmed death 1 ligand 1 surface expression in head and neck squamous cell carcinoma cells by blocking JAK2/STAT1 signaling.
    Wu Q; Zhao Y; Sun Y; Yan X; Wang P
    Oncol Rep; 2018 Mar; 39(3):1461-1468. PubMed ID: 29328389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The immune microenvironment of HPV-negative oral squamous cell carcinoma from never-smokers and never-drinkers patients suggests higher clinical benefit of IDO1 and PD1/PD-L1 blockade.
    Foy JP; Bertolus C; Michallet MC; Deneuve S; Incitti R; Bendriss-Vermare N; Albaret MA; Ortiz-Cuaran S; Thomas E; Colombe A; Py C; Gadot N; Michot JP; Fayette J; Viari A; Van den Eynde B; Goudot P; Devouassoux-Shisheboran M; Puisieux A; Caux C; Zrounba P; Lantuejoul S; Saintigny P
    Ann Oncol; 2017 Aug; 28(8):1934-1941. PubMed ID: 28460011
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Saigi M; Alburquerque-Bejar JJ; Mc Leer-Florin A; Pereira C; Pros E; Romero OA; Baixeras N; Esteve-Codina A; Nadal E; Brambilla E; Sanchez-Cespedes M
    Clin Cancer Res; 2018 Sep; 24(18):4579-4587. PubMed ID: 29898990
    [No Abstract]   [Full Text] [Related]  

  • 16. IFNγ induces PD-L1 overexpression by JAK2/STAT1/IRF-1 signaling in EBV-positive gastric carcinoma.
    Moon JW; Kong SK; Kim BS; Kim HJ; Lim H; Noh K; Kim Y; Choi JW; Lee JH; Kim YS
    Sci Rep; 2017 Dec; 7(1):17810. PubMed ID: 29259270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JAK-STAT1 Signaling Pathway Is an Early Response to
    Li X; Pan K; Vieth M; Gerhard M; Li W; Mejías-Luque R
    Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35456965
    [No Abstract]   [Full Text] [Related]  

  • 18. Tumor microenvironment in giant cell tumor of bone: evaluation of PD-L1 expression and SIRPα infiltration after denosumab treatment.
    Toda Y; Kohashi K; Yamamoto H; Ishihara S; Ito Y; Susuki Y; Kawaguchi K; Kiyozawa D; Takamatsu D; Kinoshita I; Yamada Y; Maehara J; Kimura A; Tamiya S; Taguchi K; Matsunobu T; Matsumoto Y; Nakashima Y; Mawatari M; Oda Y
    Sci Rep; 2021 Jul; 11(1):14821. PubMed ID: 34285260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salinomycin promotes T-cell proliferation by inhibiting the expression and enzymatic activity of immunosuppressive indoleamine-2,3-dioxygenase in human breast cancer cells.
    Ebokaiwe AP; Njoya EM; Sheng Y; Zhang Z; Li S; Zhou Z; Qiang Z; Peng T; Hussein AA; Zhang G; Lu X; Li L; Wang F
    Toxicol Appl Pharmacol; 2020 Oct; 404():115203. PubMed ID: 32822738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cytotoxic effects of indoleamine 2, 3-dioxygenase inhibitors on triple negative breast cancer cells upon tumor necrosis factor α stimulation.
    Bilir C; Eskiler GG; Bilir F
    J Cancer Res Ther; 2023 Apr; 19(Supplement):S74-S80. PubMed ID: 37147986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.